12:00 AM
Feb 16, 2009
 |  BioCentury  |  Emerging Company Profile

Chiome: Antibodies ad libitum

By accelerating gene conversion frequency in a chicken B cell line, Chiome Bioscience Inc. says its can generate antibodies in as little as two weeks, much faster than hybridoma- or phage display-based systems. The company has signed service agreements to generate antibodies against antigens for pharma partners, but ultimately hopes to develop its own therapeutic antibodies for Orphan cancers and immune disorders.

"We are just starting work on internal antibodies against certain antigens with a goal to focus on Orphan diseases in the cancer and immune disease space," President and CEO Masaaki Fujiwara said. "Our goal will be to be ready to move into the IND stage with lead...

Read the full 530 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >